Celebrate American Heart Month in FebruaryJanuary 31st, 2019
Global ELISA Market to Grow at a CAGR of 5.5% through 2028January 30th, 2019
MEDICA 2019 - World Forum for Medicine
Düsseldorf, GermanyBooth No.: 3/D35-2
AACC Annual Scientific Meeting and Clinical Lab Expo
Anaheim Convention Center ~ Anaheim, CABooth No.: 2627
Thanks to Block Scientific, I was able to procure the re-certified Bayer DCA 2000+ without hassles and get the lab back in operation. The
device works perfectly and I look forward to doing more business with Block Scientific.
--- Mathew Anderson, New Jersey
SEFRIA™ reagents comprise the next generation immunoassay utilizing β-galactosidase enzyme allowing for lower cutoffs, wider assay span,
and enhanced precision in a ready-to-use liquid format.
Our SEFRIA™ Fentanyl is the first-ever FDA 510(k) cleared assay designed for qualitative testing at a 1 ng/mL cutoff.
Fentanyl is a synthetic narcotic analgesic of high potency and short duration of action. The drug is available as a citrate salt in an injectable solution containing 50 μg/mL. It is also available as a transdermal patch containing 2.5–10 mg fentanyl and provides a dose of 25–100 μg/hr for 72 hours for management of chronic pain.2
While fentanyl has all the properties of morphine, it is structurally different and therefore cannot be detected by screening tests for morphine and related opiates.
Administration: Intravenous, transdermal patch, flavored lozenges, lollipop, buccal tablets, nasal spray, and inhalant.
The Immunalysis® Fentanyl Urine SEFRIA™ Drug Screening Kit detects the presence of fentanyl and its major metabolites in human urine samples with a cutoff of 1 ng/mL for qualitative testing. In clinical performance studies, testing with the Fentanyl Urine SEFRIA™ Drug Screening Kit compared favorably to liquid chromatography-mass spectrometry (LC-MS) analysis in both sensitivity (identification of positive results) and specificity (identification of negative results).